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Objective: The empiric use of antibiotics for elevated prostate speciﬁc antigen (PSA) is practiced by many
urologists worldwide. This study aims to investigate the effect of antibiotics on the degree of PSA change,
linking it with histopathology results.
Materials and Methods: This is a prospective randomized study. Patients presenting with a high PSAwere
randomized into two groups. Group 1 received antibiotics for a period of 4 weeks, while Group 2 did not
receive any antibiotics. Both groups had repeated samples of PSA measured 6 weeks from their initial
presentation. All patients underwent transrectal ultrasound-guided biopsy of the prostate. Results of PSA
measurements and the degree of change were correlated with results of histopathology.
Results: Eighty-four patients completed the study. Their mean age± standard deviation was
66.8 ± 6.9 years. Group 1 included 44 patients, while Group 2 included 42 patients. Prostate cancer (PCa)
was detected in 50% and 35.7% of Group 1 and Group 2 patients, respectively (p ¼ 0.52). No statistically
signiﬁcant difference in the mean change in PSA level (D PSA) between both groups was noted (p ¼ 0.54).
In Group 1, a more signiﬁcant lowering of PSA was documented in PCa than in non-PCa patients
(p ¼ 0.008). No statistically signiﬁcant relationship between D PSA and Gleason score in both groups was
present.
Conclusion: The empiric use of antibiotics does not hold any beneﬁt for patients presenting with an
elevated PSA. Also, the degree of change in PSA does not correlate with results of transrectal ultrasound-
guided biopsy of the prostate.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCa) is a signiﬁcant medical condition with an
increasing incidence worldwide.1 In addition to a pathologic diag-
nosis, prostate-speciﬁc antigen (PSA) measurement is considered
an essential method for detecting PCa. Although PSA is prostate
speciﬁc, it is not cancer speciﬁc, as such it can be elevated in
nonmalignant conditions such as benign prostatic enlargement and
prostatitis.2 A serum PSA value of 4 ng/mL has long been used as a
cut-off value for performing prostate biopsy; however, in recent
years the threshold has been reduced to 2.5 ng/mL as a signiﬁcant
proportion of men harbor PCa at levels lower than what was pre-
viously recommended.3
In clinical practice, many urologists tend to administer empiric
antibiotics for patients presenting with moderately elevated PSAHamad Medical Corporation,
e Box 3050, Doha, Qatar.
).
ociation. Published by Elsevier Taprincipally aiming at reducing unnecessary prostate biopsies. Few
studies have been made to provide scientiﬁc evidence for this
practice.2e7 Although most of them did ﬁnd a signiﬁcant reduction
in serum PSA after antibiotic treatment, they had one or more
weaknesses in their methodology such as retrospective design,7
absence of a control group,4 or failure of obtaining pathologic re-
sults from all participants.5,6
In this randomized prospective study we aim to evaluate the
effect of antibiotic therapy on patients presenting with an elevated
serum PSA level and perform a prostate biopsy on all participants in
an attempt to correlate histopathologic results with the degree of
PSA change.2. Materials and methods
This is a prospective randomized study conducted at the uro-
oncology unit in a tertiary care center. Between March 2011 and
December 2014, patients referred with an elevated serum PSA and
meeting the inclusion and exclusion criteria were included in this
study. The inclusion criteria were patients presenting with aniwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Comparison between study groups.
Group 1 (n ¼ 44) Group 2 (n ¼ 42) p
Age (y) 65.4 ± 6.9 64.8 ± 7.2 0.98
PSA 1 7.7 ± 2.9 7.2 ± 3.4 0.45
PSA 2 7.6 ± 3.4 7.4 ± 3.4 0.85
D PSA 0.16 ± 2.8 0.2 ± 2.4 0.54
PSA decline 27 (61) 21 (50) 0.23
Histopathology
PCa 22 (50) 15 (35.7) 0.52
BPH 22 (50) 27 (64.2)
Chronic inﬂammation 4 (9) 3 (7.1)
ASAP 2 (4.5) 2 (4.7)
Data are presented as n (%) or mean ± standard deviation.
ASAP ¼ atypical small acinar proliferation of indeterminate signiﬁcance;
BPH ¼ benign prostatic hyperplasia; Pca ¼ prostate cancer; PSA ¼ prostate speciﬁc
antigen; D PSA ¼ change in prostate speciﬁc antigen.
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criteria were the presence of symptoms of urinary tract infection or
prostatitis, history of prior prostate surgery, biopsy or radiotherapy,
any abnormal ﬁnding on digital rectal examination (DRE), urinary
catheterization during the previous 4 weeks, previous use of 5-a
reductase inhibitors, hypersensitivity to any medical ingredient in
the quinolone group, and presence of bacterial growth or pyuria in
urine samples obtained from asymptomatic patients. All study
participants signed an informed consent and the Internal Review
Board (Hamad Medical Corporation) approved the study protocol
carrying the Internal Review Board number 12144/12.
Prior to their enrollment in the study, all patients were primarily
assessed with DRE, urinalysis, and culture. Using computer gener-
ated randomization tables, eligible patients were randomly divided
into two groups. Group 1 patients received empiric antibiotic
therapywith ciproﬂoxacin 500mg twice daily for a total of 4 weeks,
while Group 2 patients did not receive any antibiotic therapy. Six
weeks after their initial presentation, a repeat serum PSA test was
performed for all patients followed by transrectal ultrasound-
guided biopsy of the prostate (TRUSBP).
PSA measurement was performed using the Architect i2000SR
analyzer (AbbottManufacturing Inc., Abilene, TX, USA). The total PSA
assay is a two-step immunoassay to determine the presence of total
PSA (both free PSA and PSA complexed to a1-antichymotrypsin) in
human serum, using a chemiluminescent microparticle immuno-
assay with ﬂexible assay protocols. This method of measurement is
easy to use, accurate, precise, and suitable for a routine clinical
laboratory.8
TRUSBP was performed according to the standards of care set by
our institute. Prophylactic antibiotics included: oral ciprofoxacin
500mg and a single intravenous injection of 1.5 g cefuroxime given
30 minutes prior to the procedure. Patients were placed in the left
lateral decubitus position, and a DRE was ﬁrst performed using
lidocaine hydrochloride 2% sterile gel (Rialocaine, Ryiadh Pharma,
Saudi Arabia) anesthetic ointment. A 7.5-MHz transducer (Accuvix
v10, Madison Ultrasound System, Samsung Town, Seoul, South
Korea) was gently advanced into the rectum and 10 mL of lidocaine
hydrochloride 2% (Xylocaine, Pharmaceutical Solutions Industry,
Jeddah, Saudi Arabia) was injected locally on both prostate edges.
After obtaining the measurements, an 18-G needle loaded in a
spring-action biopsy device was used to obtain the specimens. A
12-core biopsy is the standard at our institution.
The 12-core TRUSBP specimens were assessed for adequacy
and individually stored in different containers, each labeled with
the patient's identiﬁcation and with a number mapped according
to their designated site. The containers were assessed in the his-
topathology department and examined by a qualiﬁed pathologist
who reported the ﬁndings according to the College of American
Pathologists guidelines.9 If adenocarcinoma was diagnosed, the
report usually included the length of each biopsy and the per-
centage of cancer involvement in each biopsy, the Gleason
grade(s) and the extent of any high-grade (Gleason 4 or 5)
component, the number of biopsy cores positive for cancer, and
their location.
The ﬁrst PSA result is denoted as PSA1, while the second PSA
result as PSA2. The change in PSA (D PSA) is calculated by sub-
tracting PSA2 from PSA1. A negative result indicates a reduction in
PSA level, while a positive result indicates an elevation in PSA
level.
The data was presented as the mean (standard deviation) for
continuous variables, and the frequency and percentage for ordinal
and nominal variables. Continuous and categorical variables were
assessed using t test and Chi-square test, respectively. A p
value < 0.05 was considered statistically signiﬁcant. All data were
analyzed using SPSS version 20 (IBM, Armonk, NY, USA).3. Results
A total of 92 patients met the inclusion and exclusion criteria
and were included in the study. Eight patients were lost to follow-
up and did not attend for repeat PSA testing or TRUSBP and were
excluded from the study. The mean age± standard deviation of the
study populationwas 66.8 ± 6.9 years. Prostate cancer was detected
in 37 patients. A comparison between Group 1 and Group 2 patients
is presented in Table 1. Group 1 included 44 patients, while Group 2
included 42 patients. PCawas detected in 50% and 35.7% of Group 1
and Group 2 patients, respectively (p ¼ 0.52). A drop in PSA level
was detected in 27 (61%) patients and 21 (50%) patients of Group 1
and Group 2, respectively (p ¼ 0.23). No statistically signiﬁcant
differences in histopathology results were detected between pa-
tients with and without a drop in PSA (Figure 1).
Group 1 patients had a statistically signiﬁcant D PSA between
PCa (þPCa) and non-PCa (ePCa) patients,e1.02 ± 2.9 and 1.03± 2.4,
respectively (p¼ 0.008). No statistically signiﬁcant D PSAwas noted
in Group 2 patients (p¼ 0.77; Table 2). A correlation between D PSA
and Gleason score of PCa patients in both groups is presented in
Table 3. No statistically signiﬁcant D PSA in relation to Gleason
score was found between both groups (p ¼ 0.17).4. Discussion
Serum PSA is a nonspeciﬁc marker that can be elevated in
noncancerous conditions. This prospective randomized study ex-
plores the common use of empiric antibiotic therapy for elevated
PSA prior toTRUSBP and for the ﬁrst time correlates prostate biopsy
results, speciﬁcally Gleason score, to antibiotic use and the degree
of change in PSA. Overall, empiric therapy with ciproﬂoxacin was
not associated with statistically signiﬁcant difference in mean D
PSA before and after treatment. Paradoxically patients with PCa
who received antibiotics had a signiﬁcant reduction in their PSA
level before biopsy (D PSA ¼ 1.02 ± 2.9, p ¼ 0.008).
An understanding of the motives behind the empiric use of
antibiotics for high PSA is of great importance. Many urologists tend
to use this management strategy principally because of the pres-
ence of numerous studies linking inﬂammation in the prostate to
increased PSA levels.5,10,11 The extent of disruption of epithelial
integrity caused by inﬂammatory inﬁltrate is the main etiology
behind this observation. Subclinical prostatitis was detected in up
to 40% of patients with an elevated PSA in one study.11 Carver et al10
also reported 32% chronic prostatitis National Institute of Health
type-4 cases in a randomly chosen group of 300 men. However,
while antibiotics might be useful in bacterial prostatitis, almost all
cases of asymptomatic prostatitis (National Institute of Health
Figure 1. Correlation between the histopathology result and changes in serum pros-
tate speciﬁc antigen (PSA) levels among Group 1 patients. Yes ¼ percentage of patients
with a PSA reduction; No ¼ percentage of patients with no PSA reduction;
PCa ¼ prostate cancer.
Table 2
Correlation between change in prostate speciﬁc antigen (PSA) level and prostate
cancer (PCa) in both groups.
Group 1 (n ¼ 44) Group 2 (n ¼ 42)
þPca ePca p þPca ePca p
D PSA 1.02 ± 2.9 1.03 ± 2.4 0.008 0.08 ± 2.3 0.32 ± 2.5 0.77
Data are presented as mean ± standard deviation.
D PSA ¼ change in prostate speciﬁc antigen.
Table 3
Correlation between change in prostate speciﬁc antigen and Gleason score.
Gleason 2e6 Gleason 7 Gleason 8e10 p
Total (n ¼ 37) 0.4 ± 2.6 1.3 ± 1.4 1.7 ± 3.6 0.02
Group 1 (n ¼ 22) 0.6 ± 2.7 1.3 ± 1.6 1.7 ± 3.6 0.06
Group 2 (n ¼ 15) 0.03 ± 2.5 1.4 ± 1.2 NA 0.18
Data are presented as mean ± standard deviation.
NA ¼ not applicable.
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treatment. Additionally, other studies failed to ﬁnd a correlation
between PSA and prostate inﬂammation,13e15 depicting prostate
volume rather than inﬂammation as a major confounding factor
causing PSA elevation.
Another reason that might support the use of antibiotics is to
avoid unnecessary prostate biopsy. TRUSPB is the gold standard
procedure for PCa diagnosis.16 It is indicated in the context of serum
PSA elevation with or without abnormal DRE. Although this pro-
cedure is irreplaceable, it is still associated with various unavoid-
able complications such as sepsis, hematuria, and rectal
bleeding.17,18 Fever and sepsis are perhaps the most inﬂuential
causes of postbiopsy morbidity and the most common reason for
hospitalization after TRUSBP. Severe infections were initially re-
ported in < 1% of cases, but have increased as a consequence of
antibiotic resistance.19 In a study of 455 patients undergoing
TRUSBP, Al Rumaihi et al17 reported the occurrence of postbiopsy
fever in 5.9% of cases. An obvious increase in the overall risk of
postbiopsy infection has been noticed over the past decade. The
principle reason for this observation is the unjustiﬁed use of anti-
biotics.20 An increasing rate of quinolone resistance is present as a
dramatic 22% of men were found to have quinolone-resistant ﬂora
on prebiopsy rectal swabs.21 In a study by Song et al,22 extended
spectrum of beta lactase producing Escherichia coli were isolated
from blood samples of 95.9% of patients with postbiopsy infections.
All these reasons support against the use of empiric antibiotics forhigh PSA, as such an act may increase the risk of postbiopsy
infection with resistant organisms.
Few studies have speciﬁcally explored the use of antibiotics in
patients with an elevated PSA level. Saribacak et al2 compared 50
patients to whom ﬂuoroquinolone was administered prior to
TRUSBPwith an equal control group. A signiﬁcant PSA decreasewas
observed in the treatment group at repeat measurement and the
drop was also more signiﬁcant in patients without PCa than with
PCa. In another study, 215 culture-positive prostatitis patients with
a high PSA received 2-months treatment with levoﬂoxacillin and
were followed with another reading. A signiﬁcant reduction in PSA
level was noted to the extent that TRUSBP was not performed in 53
out of 215 patients. However, seven (4%) out of the remaining 162
patients who underwent TRUSBP had PCa.23 Azab et al4 conducted
a prospective study on 142 patients with an elevated PSA and
positive-expressed prostatic secretions. All patients received
treatment with antibiotics for 6 weeks and were followed with
another PSA reading. Despite ﬁnding a signiﬁcant decrease in PSA
level up to 41%, PCa was detected in patients with PSA levels less
than 2.5 ng/mL.
Schtricker et al7 failed to ﬁnd any advantage for administration
of antibacterial therapy. Out of 65 men who received antibiotics,
and 70 men who did not receive antibiotics, PSA reduction was
equally noticed in 40% of patients from both groups.7 This study
failed to ﬁnd any statistically signiﬁcant difference in PSA levels
between patients receiving antibiotics and patients not receiving
antibiotics (Table 1). Additionally, in patients receiving antibiotics,
PSA reduction was statistically signiﬁcant in those who were found
to have PCa (Table 2). The signiﬁcance of the latter ﬁnding suggests
that the drop in PSA after antibiotic treatment, may not necessarily
rule out cancer. In fact, a link between prostate inﬂammation and
PCa has been established which may explain why PSA may respond
to antibiotic therapy in PCa patients. A large, multiracial study re-
ported an increased risk of PCa in patients having a history of
prostatitis (relative risk¼ 1.3, 95% conﬁdence interval: 1.10e1.54).24
Furthermore, a recent study by Stark et al,25 suggested that chronic
inﬂammation may be associated with PCa progression. Unfortu-
nately, inﬂammation is commonly underreported when cancer is
detected in tissue samples, an obstacle that prevented us from
conﬁrming such an association in this study.
This is the ﬁrst study to correlate PSA change with Gleason
score. Although no statistically signiﬁcant difference in D PSA was
noticed between PCa patients from Groups 1 and 2, overall a
signiﬁcantly higher Gleason score was found in patients with the
most reduction in PSA level (Table 3). This eerie result is not
necessary uncommon. In a recent study by Izumi et al26 evaluating
642 patients who underwent TRUSBP, although not statistically
signiﬁcant, the percentage of Gleason score 8e10 in patients with a
PSA level of < 3.5 ng/mL was higher than that in patients with a PSA
level between 3.5 ng/mL and 10ng/mL. In another study evaluating
outcomes of patients with Gleason score 8e10 PCa, patients with a
PSA level  2.5 ng/mL had proportionately worse outcomes than
their counterparts with higher PSA levels.27
One limitation to this study is not using a PSA range of 4e10 ng/
mL as an inclusion criterion. However, this could also be considered
a strength as it mimics routine practice exploring the value of
empiric antibiotic therapy in such patients. Another limitation is
not using a placebo groupwhich could have made the study double
blind.
5. Conclusion
The empiric use of antibiotics for PSA elevation is not justiﬁed as
it can delay PCa diagnosis. Signiﬁcant PSA reductions existed with
PCa, and more importantly in patients with higher Gleason grades.
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